Table 1.

Patient characteristics: Cediranib treated patients

Pt#	Days on study	Time between last cediranib dose and death	Response at 28 days	Response at end-of-study#	Reason for interruption	Other treatment	Age
P1	232	27 days	PR	SD	Clinical progression	No	72
P2	226	110 days*	PR	PD	Suspected progression by MRI	CPT-11+ bevacizumab	56
P3	170	16 days	SD	PR	Infection	No	53
P4	133	42 days	PR	SD	Clinical progression	No	42
P5	56	105 days	PR	PD	Toxicity	No	46

^*although the last dose of cediranib was 110 days prior to death this patient continued to receive antiangiogenic therapy (bevacizumab) until he died.

^#relative response compared to day 28 MRI.

PR: partial response (drop in >50% of the initial tumor volume); SD: stable disease; PD: progressing disease (increase by 25%)